Literature DB >> 1822677

Classical subtypes for schizophrenia: literature review for DSM-IV.

T H McGlashan1, W S Fenton.   

Abstract

The classical subtypes of schizophrenia include the paranoid, hebephrenic, undifferentiated, residual, catatonic, and simple. This review of studies, especially those conducted during the last decade, supports the validity of the subtypes, particularly the paranoid subtype. To a lesser degree, the same holds for the hebephrenic and undifferentiated subtypes. The catatonic subtype has seldom been studied, perhaps because it is so rare. The residual and simple subtypes have not been the focus of any studies of note. Subtype criteria for DSM-IV are suggested based on the review. The paranoid and undifferentiated subtypes should be retained with criteria identical to those in DSM-III-R. The disorganized subtype also should be retained but with modified criteria that are somewhat more stringent than those in DSM-III-R. Catatonia and residual schizophrenia should remain, but insufficient data exist upon which to base any changes in criteria. Given its historical precedence, as well as the emerging importance of deficit processes in schizophrenia, simple schizophrenia should be renamed and reintroduced as a subtype in DSM-IV. Two variations in criteria are offered.

Entities:  

Mesh:

Year:  1991        PMID: 1822677     DOI: 10.1093/schbul/17.4.609

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  12 in total

Review 1.  [Deconstructing schizophrenia. Dimensional models or division into subtypes?].

Authors:  M Jäger; K Frasch; F U Lang; T Becker
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

2.  Consensus judgments of discharge readiness based on paranoid behavior: to what are clinical staff responding?

Authors:  Julian A Salinas; Gordon L Paul; Justin R Springer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

Review 3.  Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature.

Authors:  Ayman H Fanous; Kenneth S Kendler
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

Review 4.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

5.  Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.

Authors:  Victoria S Dalton; Leonora E Long; Cyndi Shannon Weickert; Katerina Zavitsanou
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

6.  Polygenic Risk Scores for Subtyping of Schizophrenia.

Authors:  Jingchun Chen; Travis Mize; Jain-Shing Wu; Elliot Hong; Vishwajit Nimgaonkar; Kenneth S Kendler; Daniel Allen; Edwin Oh; Alison Netski; Xiangning Chen
Journal:  Schizophr Res Treatment       Date:  2020-07-23

7.  GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.

Authors:  Hui Tang; Na Shen; Huijuan Jin; Dan Liu; Xiaoping Miao; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2013-02-27       Impact factor: 5.590

8.  Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.

Authors:  Sarah E Bergen; Ayman H Fanous; Dermot Walsh; F Anthony O'Neill; Kenneth S Kendler
Journal:  Schizophr Res       Date:  2009-03-05       Impact factor: 4.939

9.  Regional enrichment analyses on genetic profiles for schizophrenia and bipolar disorder.

Authors:  Jingyu Liu; Jiayu Chen; Nora I Perrone-Bizzozero; Jessica A Turner; Vince D Calhoun
Journal:  Schizophr Res       Date:  2017-04-22       Impact factor: 4.939

Review 10.  Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.

Authors:  Amber Edinoff; Miriam T Ruoff; Yahya T Ghaffar; Arthur Rezayev; Devanshi Jani; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.